Atherosclerosis
Volume 169, Issue 1 , Pages 31-40 , July 2003

Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-β in carotid artery of atherosclerotic rabbits

Received 6 February 2002 ,Revised 21 October 2002 ,Accepted 27 February 2003.

References 

  1. Bittl JA. Advances in coronary angioplasty. N. Engl. J. Med. 1996;335:1290–1302
  2. Wurdeman RL, Hilleman DE, Mooss AN. Restenosis, the Achilles' heel of coronary angioplasty. Pharmacotherapy. 1998;18:1024–1040
  3. Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog. Cardiovasc. Dis. 1997;39:361–398
  4. Bauters C, Isner JM. The biology of restenosis. Prog. Cardiovasc. Dis. 1997;40:107–116
  5. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor. VIIa. Additional pathway of initiation of blood coagulation. Proc. Natl. Acad. Sci. USA. 1977;74:5260–5264
  6. Lovqvist A, Emanuelsson H, Nilsson J, Lundqvist H, Carlsson J. Pathophysiological mechanisms for restenosis following coronary angioplasty: possible preventive alternatives. J. Intern. Med. 1993;233:215–226
  7. Mehta D, George SJ, Jeremy JY, Izzat MB, Southgate KM, Bryan AJ, et al. External stenting reduces long-term medial and neointimal thickening and platelet-derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat. Med. 1998;4:235–239
  8. Berrou E, Bryckaert M. Platelet-derived growth factor inhibits smooth muscle cell adhesion to fibronectin by ERK-dependent and ERK-independent pathways. J. Biol. Chem. 2001;276:39303–39309
  9. Ken K, Narutaka O, Norihiro I, Yoshikazu I, Akiko I, Hideki M, et al. Suppression of cell proliferation by tissue plasminogen activator during the early phase after balloon injury minimizes intimal hyperplasia in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 2001;37:155–162
  10. Rasmussen LM, Wolf YG, Ruoslahti E. Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-β activity. Am. J. Pathol. 1995;147:1041–1048
  11. Shen GX. Development and current application of thrombin-specific inhibitors. Curr. Drug Targets: Cardiovasc. Haemost. Dis. 2001;1:41–49
  12. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators, N. Engl. J. Med. 1996;335:775–82.
  13. Bittl JA, Feit F. A randomized comparison of bivaliurdin and heparin in patients undergoing coronary angioplasty for post-infarction angina. Hirulog Angioplasty Study Investigator. Am. J. Cardiol. 1998;82:43P–49P
  14. Xue M, Ren S, Welch S, Shen GX. Hirulog-like peptide reduces balloon catheter-induced neointima formation in rat carotid artery without increase in bleeding tendency. J. Vasc. Res. 2001;38:144–152
  15. Liu LY, Dai E, Hobman ML, Kolodziejczyk MD, Lucas A. Animal models of restenosis: myth or reality. Curr. Pharm. Res. 1996;2:553–584
  16. Fishman J, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of intimal thickening. Lab. Invest. 1975;32:339–351
  17. Sarembock IJ, La Veau PJ, Sigal SL, Timms I, Sussman J, Haudenschild C, et al. Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. Circulation. 1989;80:1029–1040
  18. LeVeen RF, Wolf GL, Villanueva TG. New rabbit atherosclerosis model for the investigation of transluminal angioplasty. Invest. Radiol. 1982;17:470–475
  19. Fishbein I, Waltenberger J, Banai S, Babinovich L, Chorny M, Levizki A, et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler. Thromb. Vasc. Biol. 2000;20:667–676
  20. Xue M, Fenton JW, Shen GX. Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury. J. Vasc. Res. 2000;37:87–92
  21. Holm P, Stender S, Andersen HO, Hansen BF, Nordestgaard BG. Antiatherogenic effect of estrogen abolished by balloon catheter injury in cholesterol-clamped rabbits. Arterioscler. Thromb. Vasc. Biol. 1997;17:1504–1511
  22. Fishbein I, Chorny M, Babinovich L, Banai S, Gati I, Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J. Control. Release. 2000;65:221–229
  23. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am. J. Pathol. 1989;134:1087–1097
  24. Thome LM, Gimple LW, Bachhuber BG, McNamara CA, Ragosta M, Gertz SD, et al. Early plus delayed hirudin reduces restenosis in the atherosclerotic rabbit more than early administration alone: potential implication for dosing of antithrombotic agents. Circulation. 1998;98:2301–2306
  25. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin (CGP 39393) in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232–243
  26. Ragosta M, Barry WL, Gimple LW, Gertz SD, McCoy KW, Stouffer GA, et al. Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Circulation. 1996;93:1194–2000
  27. Sarembock IJ, Gertz SD, Thome LM, McCoy KW, Ragosta M, Powers ER, et al. Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. J. Vasc. Res. 1996;33:308–314
  28. Adgey AA. Bleeding complications with new antithrombotic used in ischaemic heart disease. Haemostasis. 1996;26:237–246
  29. Alt E, Haehnel I, Beilhartz C, Prietzel K, Preter D, Stemberger A, et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprast. Circulation. 2000;101:1453–1458
  30. Kalinowski M, Alfke H, Bergen S, Klose KJ, Barry JJ, Wagner HJ. Comparative trial of local pharmacotherapy with l-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries. Radiology. 2001;219:716–723
  31. Bartha K, Brisson C, Archipoff G, de la Salle C, Lanza F, Cazenave JP, et al. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J. Biol. Chem. 1993;268:421–429
  32. Wilcox JN, Smith KM, Schwartz SM, David G. Localization of tissue factor in normal vessel wall and in atherosclerotic plaque. Proc. Natl. Acad. Sci. USA. 1989;86:2839–2843
  33. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Thomas H. Evidence for the presence of tissue factor activity on subendothelium. Blood. 1989;73:968–975
  34. Gertz SD, Fallon JT, Gallo R, Taubman MB, Banai S, Barry WL, et al. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. Circulation. 1998;98:580–587
  35. Oltrona L, Speidel CM, Recchia D, Samuel AW, Paul RE, Dana RA. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation. 1997;96:646–652
  36. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92:3041–3050
  37. Grandaliano G, Gesualdo L, Schena FP. Thrombin: a novel renal growth factor. Exp. Nephrol. 1999;7:20–25
  38. Kranzhofer R, Maraganore JM, Baciu R, Libby P. Systemic thrombin inhibitor by hirulog does not alter medial smooth muscle proliferation and inflammatory activation after vascular injury in the rabbit. Cardiovasc. Drugs Ther. 1999;13:429–434
  39. Stouffer GA, Runge MS. The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells. Semin. Thromb. Haemost. 1998;24:145–150
  40. Batchelor WB, Robinson R, Strauss BH. The extracellular matrix in balloon arterial injury: a novel target for restenosis prevention. Prog. Cardiovasc. Dis. 1998;41:35–49
  41. Libby P, Tanaka H. The molecular base of restenosis. Prog. Cardiovasc. Dis. 1997;40:97–106
  42. Gibbon GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J. Clin. Invest. 1992;90:456–461
  43. Border WA, Russlahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest. 1992;90:1–7
  44. Bachhuber BG, Sarembock IJ, Gimple LW, Owens GK. Alpha-thrombin induces transforming growth factor-beta1 mRNA and protein in cultured vascular smooth muscle cells via proteolytically activated receptor. J. Vasc. Res. 1997;34:41–48
  45. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease activated receptor-1. J. Biol. Chem. 2000;275:35584–35591

PII: S0021-9150(03)00105-9

doi: 10.1016/S0021-9150(03)00105-9

Atherosclerosis
Volume 169, Issue 1 , Pages 31-40 , July 2003

Article Tools

* Image Usage & Resolution